Bio Blast Pharma (ORPN) Reports Q1 Loss of 23c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Roth Affirms BioBlast Pharma (ORPN) at 'Buy' Following Q1 Report; U.S. Phase II/III HOPEMD Enrollment Remains Next Milestone
May 19, 2015 11:10 AM EDTRoth Capital affirms its Buy rating and $18 price target on BioBlast Pharma Ltd. (Nasdaq: ORPN) following hte company's Q1 report, which was issued ahead of the opening bell on Tuesday.
Analyst Joseph Pantginis noted that BioBlast's Q1 loss of $0.23 per share was 1 cent better than the firm's loss estimate.
Pantginis commented, We look forward to ORPN's next operational milestone, the opening of the U.S. Phase II/III HOPEMD site in California with enrollment expected to... More
